< Back to latest news & events

News

The Vedanta Opposition: A healthy sign of a maturing industry

September 2019

HGF Partners Craig Thomson and Rachel Fetches comment and analyse the “Vedanta Opposition” in Microbiome Times.

As we move towards marketing approval for microbiome therapeutics, the “value” of the microbiome industry is increasing exponentially. This will inevitably result in disputes between the leading competitors seeking to protect their key intellectual property (IP) rights, including patent monopoly rights.

The most significant challenge to patent rights in the therapeutic microbiome field to-date is the recently issued decision in the “Vedanta Opposition”. The patent (European Patent No. 2575835) was granted to the University of Tokyo (UoT) in October 2016.

Within the 9-months after grant, the European Patent Office (EPO) received six Oppositions from Seres Therapeutics, Nestec and four anonymous parties. The Opposition hearing lasted three days and almost 130 documents were considered. Ultimately, the patent was maintained by the EPO’s Opposition Division (OD) but in an amended form, with a narrowed claim scope; this decision has been appealed and it will likely be at least 2 years until the Appeal is heard.

Some elements of the claims raise difficulties for prospective patentees in the microbiome field as it enforces second use claims of this type in the national courts. Where does the OD’s decision leave Vedanta commercially?

Read the full article here.

Latest updates

PRESS RELEASE - HGF Appoints new Chair of the Board: Formerly Head of Engineering, Lucy Johnson

HGF announced a new Chair to its Management Board, Lucy Johnson. Lucy was previously head of the firm’s Engineering Group.  Effective immediately Lucy succeeds Jason Lumber who held the position …

Read article

Celebrating Success in the Pharmaceuticals Industry: Jazz Pharmaceuticals Enters Deal With Redx

HGF would like to congratulate Redx Pharmaceuticals on their recent deal with Jazz Pharmaceuticals concerning the global rights to Redx’s KRAS Inhibitor Program. This partnership has the potential to provide …

Read article

What's Next for CAR Cell Therapy?

The first generation CAR T cell was discovered in 1993 when the variable region of an antibody was fused to the constant regions of a T cell receptor.  Now, 20 …

Read article

Blog Series: IP Ingredients, Part 7: Data in food and beverage patent applications - Why, What & How much?

Questions I often get asked by innovators looking to file a patent application include: “What kind of experimental data do I need to include?” and “How many examples do we …

Read article

HGF ranked in The Legal 500 Germany 2024

HGF is proud to be ranked in The Legal 500 Germany 2024 guide. The Legal 500 provides the most comprehensive worldwide coverage on recommended Law firms, Lawyers, Attorneys, Advocates, Solicitors, …

Read article

EPO Annual Fee Increases

The European Patent Office (EPO) has announced that revised Official Fees will apply to payments made on or after Monday 1st April 2024. The majority of fees will increase by …

Read article

Tanya Waller Recognised as Lexology Legal Influencer for IP

We are delighted to share that our Trade Mark Director Tanya Waller has been recognised as a Lexology Legal influencer for Q4/2023! Tanya provides high-quality legal content for our website …

Read article